Genmab A/S and Pharming Group N.V.: SG&A Spending Patterns Compared

Biotech Giants' SG&A Spending: A Decade of Divergence

__timestampGenmab A/SPharming Group N.V.
Wednesday, January 1, 2014795290004042025
Thursday, January 1, 2015912240005279557
Friday, January 1, 20161024130008073913
Sunday, January 1, 201714698700044864073
Monday, January 1, 201821369500053488904
Tuesday, January 1, 201934200000065896361
Wednesday, January 1, 202066100000069968267
Friday, January 1, 2021128300000092047281
Saturday, January 1, 20222676000000131819000
Sunday, January 1, 2023329700000087501000
Monday, January 1, 20243790000000
Loading chart...

Unlocking the unknown

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Genmab A/S and Pharming Group N.V. have showcased contrasting trajectories in their SG&A expenditures.

Genmab A/S has seen a staggering increase in SG&A expenses, growing from approximately $80 million in 2014 to over $3.3 billion by 2023. This represents a growth of over 4,000%, highlighting Genmab's aggressive expansion and investment in administrative capabilities. In contrast, Pharming Group N.V. has maintained a more conservative approach, with SG&A expenses rising from around $4 million in 2014 to about $88 million in 2023, a growth of roughly 2,100%.

This divergence in spending patterns reflects differing strategic priorities and market positions, offering valuable insights into the operational strategies of these two biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025